Search our Database of Scientific Publications and Authors

I’m looking for a

    1416 results match your criteria Paronychia

    1 OF 29

    Dermoscopic Features of Tungiasis.
    J Eur Acad Dermatol Venereol 2018 Feb 11. Epub 2018 Feb 11.
    Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
    Tungiasis is a parasitic infection caused by the sand flea Tunga penetrans. Tungiasis is prevalent in rural Central and South America, the Caribbean and sub-Saharan Africa.In some endemic areas, the overall infestation prevalence exceeds 50 percent, and it remains an important public health problem for poor communities. Read More

    A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.
    Med Oncol 2018 Feb 8;35(3):34. Epub 2018 Feb 8.
    Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, 5, Zaifu-cho, Hirosaki, 036-8562, Japan.
    This phase I trial was conducted to determine the maximum tolerated dose (MTD) and recommended dose of afatinib for phase II trial in elderly patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The study used a standard 3 + 3 dose escalation design. Patients aged 75 years or older with advanced NSCLC harboring EGFR mutations were enrolled. Read More

    Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis.
    Oncology 2018 Jan 23. Epub 2018 Jan 23.
    Oncology Unit, Oncology Department, ASST Ospedale di Cremona, Cremona, Italy.
    Background: Over the last few years only one large randomized phase III study has tried to prospectively assess the safety of cetuximab and panitumumab in a head-to-head comparison. Despite the similar overall toxicity profile, cetuximab and panitumumab retain peculiar safety characteristics that deserve to be deeply investigated.

    Methods: We conducted a systematic review for randomized trials in PubMed, the Cochrane Central Register of Controlled Trials, SCOPUS, Web of Science, and EMBASE using the terms ("cetuximab" or "panitumumab") AND ("colorectal cancer" OR "colorectal carcinoma"). Read More

    Toe keloid after nail extraction treated with surgical excision: A case report.
    Medicine (Baltimore) 2017 Dec;96(51):e9373
    Department of Plastic Surgery, Peking Union Medical College Hospital.
    Rationale: In this study, a case of toe keloid after nail extraction is presented, in which the keloids on both toes were resected by surgical excision. Keloids (from the Greek word meaning "crab's claw") are fibrous growths that extend beyond the original area of injury to involve the adjacent normal skin. In general, keloid tendencies appear to be regionally isolated to keloid-prone areas, such as the chest, ears, and deltoid regions, whereas the hands and feet are usually spared, which is why this case is meaningful. Read More

    Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.
    Psoriasis (Auckl) 2017 16;7:51-63. Epub 2017 Oct 16.
    Department of Dermatology, Inselspital, University of Bern, Bern, Switzerland.
    Psoriasis is the skin disease that most frequently affects the nails. Depending on the very nail structure involved, different clinical nail alterations can be observed. Irritation of the apical matrix results in psoriatic pits, mid-matrix involvement may cause leukonychia, whole matrix affection may lead to red lunulae or severe nail dystrophy, nail bed involvement may cause salmon spots, subungual hyperkeratosis, and splinter hemorrhages, and psoriasis of the distal nail bed and hyponychium causes onycholysis whereas that of the proximal nail fold causes psoriatic paronychia. Read More

    Osimertinib in patients with EGFR T790M advanced non-small cell lung cancer selected using cytology samples.
    Cancer Sci 2018 Jan 24. Epub 2018 Jan 24.
    Research and Development, AstraZeneca K.K, Osaka, Japan.
    Osimertinib is a potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI sensitizing (EGFRm) and T790M resistance mutations. The primary objective of the cytology cohort in the AURA study was to investigate safety and efficacy of osimertinib in pretreated Japanese patients with EGFR T790M mutation-positive NSCLC, with screening EGFR T790M mutation status determined from cytology samples. The cytology cohort was included in the Phase I dose expansion component of the AURA study. Read More

    Nail changes in autoimmune blistering disorders: A case-control study.
    Indian J Dermatol Venereol Leprol 2018 Jan 12. Epub 2018 Jan 12.
    Department of Dermatology, Venereology and Leprosy, Yenepoya Medical College, Yenepoya University, Mangalore, Karnataka, India.
    Background: Pemphigus and pemphigoid disorders produce blistering cutaneous lesions. Earlier case reports state that nail involvement is uncommon in these autoimmune blistering disorders.

    Aims And Objectives: To study nail changes in autoimmune blistering disorders. Read More

    A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Lung Cancer 2018 Jan 28;115:103-108. Epub 2017 Nov 28.
    Department of Respiratory Medicine and Allergy, Okayama University Hospital, 2-5-1, Shikata-cho, Okayama, Japan.
    Objective: In advanced epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), treatment with afatinib, a second-generation EGFR-tyrosine kinase inhibitor (TKI), confers a significant survival benefit over platinum-based chemotherapy. The first-generation EGFR-TKIs gefitinib and erlotinib in combination with bevacizumab have improved progression-free survival. We hypothesized that the combination of afatinib with bevacizumab would further improve efficacy, and conducted a phase I trial to test this hypothesis. Read More

    Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
    J Clin Oncol 2017 Dec 15:JCO2017747824. Epub 2017 Dec 15.
    Stephen R.D. Johnston, The Royal Marsden NHS Foundation Trust, London; Lisa S. Williams, Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom; Roberto Hegg, Centro de Referência da Saúde da Mulher; Sergio D. Simon, Hospital Israelita Albert Einstein, São Paulo, Brazil; Seock-Ah Im, Seoul National University College of Medicine, Seoul; In Hae Park, National Cancer Center, Gyeonggi-do, Korea; Olga Burdaeva, Regional Oncology Dispensary, Arkhangelsk; Sergei Tjulandin, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Galina Kurteva, University Cancer Center Hospital, Sofia, Bulgaria; Michael F. Press, University of Southern California, Los Angeles, CA; Hiroji Iwata, Aichi Cancer Center Hospital, Aichi, Japan; Sarah Kenny, Severine Sarp, and Miguel A. Izquierdo, Novartis Pharma AG, Basel, Switzerland; and William J. Gradishar, Northwestern University, Chicago, IL.
    Purpose Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor (HR)-positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade enhances clinical benefit versus single HER2 blockade. The ALTERNATIVE study evaluated the efficacy and safety of dual HER2 blockade plus aromatase inhibitor (AI) in postmenopausal women with HER2-positive/HR-positive MBC who received prior ET and prior neo(adjuvant)/first-line trastuzumab (TRAS) plus chemotherapy. Read More

    Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.
    Lung Cancer 2017 Oct 23;112:195-199. Epub 2017 Aug 23.
    Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road Washington DC 20007, USA. Electronic address:
    Background: Dacomitinib is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Pre-clinical data suggest that intermittent pulsatile dosing of dacomitinib may result in inhibition of EGFR T790M.

    Methods: We evaluated safety, pharmacokinetics and efficacy of intermittent pulsatile dacomitinib in both molecularly unselected patients and patients with lung cancers harboring EGFR T790M (Clinical Trial Registration Number NCT01858389). Read More

    Skin Manifestations of Targeted Antineoplastic Therapy.
    Curr Probl Dermatol 2018 7;53:93-104. Epub 2017 Nov 7.
    Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain.
    The management of oncology patients has changed significantly over recent years, with the development of new targeted anticancer therapies. Cutaneous adverse effects are among the most frequently observed toxicities with many targeted agents; their intensity can be dose-limiting or lead to the discontinuation of therapy. Tyrosine kinase inhibitors can cause maculopapular rash and hand-foot reaction, whereas papulopustular rash, paronychia, regulatory changes in hair, and dryness are caused by epidermal growth factor receptor inhibitors. Read More

    Paronychia with Sporangium Formation Causing an Ingrown Toenail A Rare Case Report.
    J Am Podiatr Med Assoc 2017 Nov 8. Epub 2017 Nov 8.
    § Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan Division of Plastic Surgery, Department of Surgery.
    Ingrown toenail, or onychocryptosis, is a common inflammatory disease of the hallux. It results from the alteration of fit of the nail plate in the lateral nail fold. They are usually seen in adolescents and young adults and can affect daily activities and social life. Read More

    Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Lung Cancer 2017 Nov 31;113:51-58. Epub 2017 Aug 31.
    University of Groningen and University Medical Center Groningen, Hanzeplein 1, Groningen, The Netherlands. Electronic address:
    Objectives: In a phase Ib trial, afatinib plus cetuximab demonstrated promising clinical activity (objective response rate [ORR]: 29%; median progression-free survival [PFS]: 4.7 months) in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) with acquired resistance to erlotinib or gefitinib. Here, a separate cohort exploring afatinib plus cetuximab after progression on afatinib is reported. Read More

    Ultrasonographic Criteria for Diagnosing Unilateral and Bilateral Retronychia.
    J Ultrasound Med 2017 Nov 1. Epub 2017 Nov 1.
    Department of Dermatology, Faculty of Medicine, University of Chile, Santiago, Chile.
    Objectives: To assess the main characteristics of retronychia on ultrasonography (US) and to propose US criteria for diagnosing unilateral and bilateral cases according to the digit.

    Methods: We conducted a case-control study with retrospective, descriptive, and statistical analyses of the US images of 210 nails: 43 with retronychia and 167 normal nails. The Student t test, Fisher exact test, and Kruskal-Wallis test, among other tests, were performed. Read More

    Clinical Mimics: An Emergency Medicine-Focused Review of Cellulitis Mimics.
    J Emerg Med 2017 Oct;53(4):475-484
    Department of Emergency Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas.
    Background: Cellulitis is a common clinical condition with low rates of morbidity and mortality if treated appropriately. Mimics of cellulitis presenting with erythema, edema, warmth, and pain can be associated with grave morbidity and mortality if misdiagnosed.

    Objective: This review investigates the signs and symptoms of cellulitis, mimics of cellulitis, and an approach to the management of both cellulitis and its mimics. Read More

    Staphylococcus lugdunensis Infections of the Skin and Soft Tissue: A Case Series and Review.
    Dermatol Ther (Heidelb) 2017 Dec 11;7(4):555-562. Epub 2017 Oct 11.
    Department of Dermatology, University of California San Diego, La Jolla, CA, USA.
    Introduction: Staphylococcus lugdunensis (S. lugdunensis) is a coagulase-negative, Gram-positive bacterium that can be isolated as a component of normal skin flora in humans. However, more recently, it has also been documented as a culprit in skin and soft tissue infections. Read More

    Primary Cutaneous CD8+ T-cell Lymphoma, an Indolent and Locally Aggressive Form Mimicking Paronychia.
    Am J Dermatopathol 2017 Sep 28. Epub 2017 Sep 28.
    Departments of *Dermatology and Cutaneous Biology, †Medical Oncology, and ‡Radiation Oncology, Thomas Jefferson University, Philadelphia, PA.
    CD8 T-cell lymphomas comprise a wide spectrum of lymphomas, many which have yet to be formally classified. We present a case of a 43-year-old woman with an enlarging tumor distal to the distal interphalangeal joint of the fourth finger, compressing the underlying nail matrix. Magnetic resonance imaging showed bony involvement of the underlying distal phalanx. Read More

    Antibiofilm activity of propolis extract on Fusarium species from onychomycosis.
    Future Microbiol 2017 Nov 4;12:1311-1321. Epub 2017 Oct 4.
    Laboratory of Medical Mycology, Departamento de Análises Clínicas e Biomedicina, Universidade Estadual de Maringá (UEM), Avenida Colombo, 5790, Maringá, PR, CEP 87020-900, Brazil.
    Aim: The present study evaluated the capacity of three species of Fusarium isolated from onychomycosis to form biofilms and the antibiofilm effect of propolis extract on these biofilms.

    Materials & Methods: The biofilms and antibiofilm effects were evaluated by quantifying the colony-forming units, mitochondrial metabolic activity assays, total biomass by crystal violet staining and scanning electron microscopy.

    Results: Propolis extract demonstrated significant antibiofilm efficiency on Fusarium spp. Read More

    Chinese Medicine Treatment for Afatinib-Induced Paronychia.
    Case Rep Oncol Med 2017 29;2017:7327359. Epub 2017 Aug 29.
    Department of Traditional Chinese Medicine, Taipei Medical University Hospital, Taipei 11031, Taiwan.
    Afatinib (Gilotrif™) is widely used to treat patients with mutant activating epidermal growth factor receptor- (EGFR-) dependent lung adenocarcinoma; however, it has various adverse side effects. Here, we report a patient with afatinib-induced paronychia. After Chinese medicine treatment with the well-known anticancer Chinese herbs, Jen-Ren-Hwo-Minq-Saan, and decoction of Ban-Zhi-Lianwith Bai-Hua-She-She-Cao (Willd), patient's condition was significantly improved. Read More

    Diffuse Palmoplantar Keratoderma, Onychodystrophy, universal Hypotrichosis and Cysts.
    Acta Dermatovenerol Croat 2017 Jul;25(2):161-163
    Assist. Prof. Tasleem Arif, MD, MBSS (Dermatology, STD AND Leprosy) Postgraduate Department of Dermatology, STDs and Leprosy Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, India;
    Dear Editor, Clouston syndrome, also called hidrotic ectodermal dysplasia (HED), is an autosomal dominant ectodermal dysplasia characterized by a clinical triad of onychodystrophy, generalized hypotrichosis, and palmoplantar keratoderma (1). Herein we report the case of a 24-year-old male with the distinctive clinical triad associated with multiple epidermoid cysts, which probably reflects the phenotype of Clouston syndrome. A 24-year-old male presented to our Department with diffuse thickening of the skin of his palms and soles since infancy. Read More

    Efficacy of Topical Compound Danxiong Granules for Treatment of Dermatologic Toxicities Induced by Targeted Anticancer Therapy: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Evid Based Complement Alternat Med 2017 6;2017:3970601. Epub 2017 Aug 6.
    Department of Pharmacy, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
    Dermatologic toxicities resulting in dose reduction or discontinuation of treatment pose challenges for targeted anticancer therapies. We conducted this randomized, double-blind, placebo-controlled trial to investigate the efficacy of topical application of Compound Danxiong Granules (CDG) for treatment of dermatologic toxicities associated with targeted anticancer therapies. One hundred and ten patients with dermatologic toxicities induced by targeted anticancer therapies were randomly assigned to CDG or placebo group. Read More

    Chemotherapy-associated paronychia treated with 2% povidone-iodine: a series of cases.
    Cancer Manag Res 2017 26;9:225-228. Epub 2017 Jun 26.
    Veloce BioPharma LLC, Fort Lauderdale, FL.
    Background: Nail changes are known to occur during the use of chemotherapy for a variety of malignancies, particularly those treated with taxanes and EGFR inhibitors. There are currently no actively recruiting prospective clinical trials investigating potential treatments. There are also no US Food and Drug Administration-approved medical treatments for chemotherapy-associated paronychia and no consensus on the best way to treat these common chemotherapy-induced events. Read More

    Neonatal Acute Paronychia.
    Hand (N Y) 2017 Sep 16;12(5):NP99-NP100. Epub 2017 Feb 16.
    1 West Virginia University School of Medicine, Morgantown, USA.
    Background: Paronychia is defined as infection afflicting the eponychial nail folds of the hand or foot. Such infections are rarely reported in the perinatal age group, and not previously described in a neonate younger than 2 weeks. Trauma resulting in inoculation of the nail fold is the most common predisposing factor to paronychia. Read More

    Acute and Chronic Paronychia.
    Am Fam Physician 2017 Jul;96(1):44-51
    Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
    Paronychia is inflammation of the fingers or toes in one or more of the three nail folds. Acute paronychia is caused by polymicrobial infections after the protective nail barrier has been breached. Treatment consists of warm soaks with or without Burow solution or 1% acetic acid. Read More

    Recurrent Paronychia as a Presenting Manifestation of Pemphigus Vulgaris: A Case Report.
    Skin Appendage Disord 2017 Mar 19;3(1):28-31. Epub 2017 Jan 19.
    Skin Disease Centre, Nashik, India.
    Nail involvement in pemphigus vulgaris (PV) is an unusual clinical finding. The most common clinical manifestations include chronic paronychia and onychomadesis. We report an adult female patient with PV who initially presented with chronic paronychia of multiple fingernails and toenails before the onset of vesiculobullous eruptions. Read More

    Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
    J Oncol Pharm Pract 2017 Jan 1:1078155217712401. Epub 2017 Jan 1.
    1 Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
    Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in patients failing previous TKI therapy. The T790M mutation is an acquired resistance mechanism found in over half of patients with NSCLC progressing on first-generation TKIs. First- and second-generation TKIs do not inhibit the T790M mutation at clinically relevant concentrations. Read More

    Acute finger-tip infection: Management and treatment. A 103-case series.
    Orthop Traumatol Surg Res 2017 Oct 26;103(6):933-936. Epub 2017 May 26.
    Centre de la main, chirurgie de la main, 47, rue de la Foucaudière, 49800 Trélaze, France.
    Introduction: Acute fingertip infections (AFTI) are common. Surgical treatment is the norm in case of effusion. There is, however, no consensus on treatment modalities, or on adjuvant antibiotic therapy (AT). Read More

    Periungual tegumentary leishmaniasis: a diagnostic challenge.
    An Bras Dermatol 2017 Mar-Apr;92(2):268-269
    Department of Clinical Medicine, Dermatology Unit, of the School of Medical Sciences of the State University of Campinas (Unicamp) - Campinas (SP), Brazil.
    Periungual and paronychia-like skin lesions can mimic various diseases, setting up a diagnostic challenge that invariably requires correlation with complementary tests. We report a case of an ulcerated tumor of the nailfold diagnosed as leishmaniasis. Although paronychia-like cutaneous leishmaniasis is a rare variant, its epidemiological relevance in Brazil should prompt dermatologists to include it as a plausible diagnosis thus leading to correct work up and treatment. Read More

    Microbiological analysis of acute infections of the nail fold on the basis of bait thread test.
    Postepy Dermatol Alergol 2017 Apr 13;34(2):110-115. Epub 2017 Apr 13.
    Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland.
    Introduction: An acute infection of the nail fold, called paronychia, is a common clinical problem. The basis for the implementation of the treatment is the result of microbiological examination. Due to the rapid and painful course of infection, usually an empirical antimicrobial treatment prior to obtaining microbiological test results is introduced. Read More

    A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy.
    Breast Cancer Res Treat 2017 Aug 9;164(3):617-625. Epub 2017 May 9.
    Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
    Purpose: Onycholysis and other nail toxicities occur in approximately 20-30% of breast cancer (BC) patients receiving docetaxel chemotherapy. Onycholysis is often associated with painful paronychia, decreasing patients' quality of life. In this study, we aimed to evaluate the efficacy of hydrating nail solution (HNS) (EVONAILsolution, Evaux Laboratories, France) for the prevention and treatment of docetaxel-induced onycholysis and nail toxicities. Read More

    Ethnopharmacological survey of medicinal plants practiced by traditional healers and herbalists for treatment of some urological diseases in the West Bank/Palestine.
    BMC Complement Altern Med 2017 May 8;17(1):255. Epub 2017 May 8.
    Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, P.O. Box 7, Palestine.
    Background: Throughout history, every civilization in the world used plants or their derivatives for treatment or prevention of diseases. In Palestine as in many other countries, herbal medicines are broadly used in the treatment of wide range of diseases including urological diseases. The main objective of this research is to study the use of herbal remedies by herbalists and traditional healers for treatment of various urological diseases in the West Bank regions of Palestine and to assess their efficacy and safety through the literature review of the most cited plants. Read More

    Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.
    Asia Pac J Clin Oncol 2018 Feb 2;14(1):23-31. Epub 2017 May 2.
    Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore.
    Patients with advanced stage non-small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations using EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib and afatinib as first-line treatment had better progression-free survival, overall response rate and quality of life than those on chemotherapy. Although EGFR TKIs are commonly associated with skin-related (rash, xerosis and paronychia) and gastrointestinal-related (diarrhea and stomatitis) adverse events (AEs), these effects are usually mild. But severe cases can occur, significantly affecting patient's well-being, treatment compliance and quality of life. Read More

    Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.
    Front Med (Lausanne) 2017 5;4:36. Epub 2017 Apr 5.
    Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain.
    Dacomitinib is a second-generation, irreversible, covalent pan-HER tyrosine-kinase inhibitor (TKI). It showed potent EGFR signaling inhibition in experimental models, including first-generation TKI-resistant non-small cell lung cancer (NSCLC) cell lines. This preclinical efficacy did not translate into clinically meaningful treatment benefits for advanced, pretreated, molecularly unselected NSCLC patients enrolled in two parallel phase III trials. Read More

    Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities.
    J Formos Med Assoc 2017 Jun 27;116(6):413-423. Epub 2017 Mar 27.
    Department of Dermatology, Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan.
    Background/purpose: This report describes the 2016 consensus of the Taiwanese Dermatological Association (TDA) regarding the definition, classification, diagnosis, prevention, and management of skin toxicities resulting from treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This consensus is distributed to practices throughout Taiwan to provide recommendations for the diagnosis and treatment of such skin toxicities in order to improve the quality of life of patients undergoing EGFR-TKI treatment. The consensus thus serves as an important reference for dermatologists and other interested clinicians, such as oncologists, throughout Taiwan. Read More

    Development of Photoonycholysis with Vandetanib Therapy.
    Skin Appendage Disord 2017 Jan 3;2(3-4):146-151. Epub 2016 Nov 3.
    Department of Oncodermatology, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France; Department of Medical Oncology and Clinical Research, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
    Vandetanib therapy is a novel once-daily oral multitargeted tyrosine kinase inhibitor, which is currently used in advanced or metastatic medullary thyroid cancer. Skin toxicities are among the most prevalent adverse events reported with this targeted therapy (e.g. Read More

    Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
    J Cancer Res Clin Oncol 2017 Jun 14;143(6):1023-1034. Epub 2017 Feb 14.
    1. Med. Klinik, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Germany.
    Purpose: Cetuximab-induced skin rash Gd3+ occurs in ≥16% patients (pts) (Heinemann et al., Lancet Oncol 15(10):1065-1075, 2014; Van Cutsem et al. J Clin Oncol 27(19):3117-25; 2009b). Read More

    Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care.
    Nurs Clin North Am 2017 03;52(1):83-113
    Department of Nursing Research, Memorial Sloan Kettering Cancer Center, 205 East 64th Street, Room 251 Concourse Level, New York, NY 10065, USA.
    Cancer treatments usually have side effects of bone marrow depression, mucositis, hair loss, and gastrointestinal issues. Rarely do we think of skin side effects until patients have been treated successfully with epidermal growth factor receptor inhibitors (EGFRi). Those reactions include papulopustular rash, hair changes, radiation dermatitis enhancement, pruritus, mucositis, xerosis, fissures, and paronychia. Read More

    De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab.
    Nephrology (Carlton) 2017 Feb;22 Suppl 1:23-27
    Department of Nephrology, Monash Health, Melbourne, Victoria, Australia.
    Thrombotic microangiopathy (TMA) is a well-recognised complication following transplantation, often due to an underlying genetic predisposition, medications or rejection. The use of eculizumab in these settings has been previously described, but its role still remains to be clarified. A 45-year-old man, with a history of type 1 diabetes mellitus and subsequent end-stage kidney failure, presented for a simultaneous pancreas-kidney transplant. Read More

    MDCT of hand and wrist infections: emphasis on compartmental anatomy.
    Clin Radiol 2017 Apr 6;72(4):338.e1-338.e9. Epub 2017 Jan 6.
    The Russell H. Morgan Department of Radiology & Radiological Science, The Johns Hopkins University School of Medicine, 601 North Wolfe Street, Baltimore, MD 21287, USA.
    Hand and wrist infections can present with a spectrum of manifestations ranging from cellulitis to deep-space collections. The various infectious processes can be categorised as superficial or deep infections based on their respective locations relative to the tendons. Superficial hand infections are located superficial to the tendons and are comprised of cellulitis, lymphangitis, paronychia, pulp-space infections, herpetic whitlow, and include volar as well as dorsal subcutaneous abscesses. Read More

    Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients.
    Dermatol Ther (Heidelb) 2017 Mar 21;7(1):133-141. Epub 2016 Dec 21.
    Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
    Introduction: Cutaneous side effects caused by epidermal growth factor receptor (EGFR) inhibitors occurred in 45-100% of patients which may lead to therapy modification or interruption. This study aimed to evaluate cutaneous side effects and transepidermal water loss (TEWL) values in non-small cell lung carcinoma (NSCLC) patients who received gefitinib EGFR inhibitor.

    Methods: A descriptive observational study with cross-sectional design and a consecutive sampling method was conducted from 1 February to 4 March 2016. Read More

    Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors.
    Pediatr Dermatol 2017 Jan 16;34(1):90-94. Epub 2016 Dec 16.
    Division of Pediatric Dermatology, Department of Dermatology, University of Minnesota, Minneapolis, Minnesota.
    Background: The mitogen-activated protein kinase (MAPK) pathway is a target for the treatment of a growing number of malignancies. The cutaneous reactions to medications that inhibit this pathway have not been described in children.

    Methods: A retrospective chart review was completed for eight children with neural tumors treated with the MAPK extracellular signal-regulated kinase inhibitor trametinib. Read More

    Clindamycin-induced acute generalised exanthematous pustulosis: five cases and a review of the literature.
    Neth J Med 2016 Dec;74(10):421-428
    1Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands.
    Acute generalised exanthematous pustulosis (AGEP) is a rare but serious cutaneous adverse drug reaction, often related to antibiotics such as beta-lactams or macrolides. However, it is rarely associated with clindamycin which belongs to the lincosamide antibiotics. The Netherlands Pharmacovigilance Centre Lareb received five reports of AGEP associated with the use of clindamycin. Read More

    LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.
    Cancer Chemother Pharmacol 2017 Jan 9;79(1):131-138. Epub 2016 Dec 9.
    Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
    Purpose: Human epidermal growth factor receptor 3 (HER3) has been identified as an important component of many receptor tyrosine kinase-driven cancers. LJM716 is a human IgG monoclonal antibody that binds HER3, trapping it in an inactive conformation. In this study, a phase I dose escalation was performed with a primary objective to establish the maximum tolerated dose and/or the recommended dose of LJM716 in Japanese patients with selected advanced solid tumors. Read More

    A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
    Invest New Drugs 2017 02 16;35(1):68-78. Epub 2016 Nov 16.
    University of California - San Francisco, Box 1705, UCSF, San Francisco, CA, 94143-1705, USA.
    Background HER3/EGFR heterodimers have been implicated as a mode of resistance to EGFR-directed therapies. Methods This Phase 1 trial assessed the tolerability, maximum tolerated dose (MTD) and pharmacokinetic (PK) properties of the HER-3 antibody seribantumab in combination with cetuximab (Part I) or cetuximab and irinotecan (Part II) in patients with EGFR-dependent cancers. In Part I, escalating doses of seribantumab and cetuximab were administered. Read More

    Allergic contact dermatitis from acrylic nails in a flamenco guitarist.
    Occup Med (Lond) 2016 Dec 7;66(9):751-753. Epub 2016 Nov 7.
    Dermatology Department, University Hospital of Guadalajara, Guadalajara 19002, Spain.
    Acrylates are molecules that are well known for their strong sensitizing properties. Historically, many beauticians and individuals using store-bought artificial nail products have developed allergic contact dermatitis from acrylates. More recently, the use of acrylic nails among flamenco guitarists to strengthen their nails has become very popular. Read More

    1 OF 29